Expertise in
8
conditions

Dr. John C. Ruckdeschel

Oncology | Hematology Oncology
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Fox Chase Cancer Center
333 Cottman Avenue, 
Philadelphia, PA 

Overview

John Ruckdeschel is an Oncologist and a Hematologist Oncology provider practicing medicine in Philadelphia, Pennsylvania.

Dr. Ruckdeschel is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Dr. Ruckdeschel is board certified in American Board Of Internal Medicine - Medical Oncology and American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 13 clinical trials.

Specialties

Oncology
Hematology Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine - Medical Oncology
American Board Of Internal Medicine - Internal Medicine

Hospital Affiliations

Temple University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Fox Chase Cancer Center
333 Cottman Avenue, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Terminated
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Unstructured Data Are Superior to Structured Data for Eliciting Quantitative Smoking History From the Electronic Health Record.
Unstructured Data Are Superior to Structured Data for Eliciting Quantitative Smoking History From the Electronic Health Record.
Journal: JCO clinical cancer informatics
Published: February 22, 2023
Similar Doctors
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Referral may be required
Before you request

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (8.7 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Margaret Kasner is a Hematologist Oncology specialist and a Palliative Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Kasner is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is board certified in Hematology and Medical Oncology. Dr. Kasner is currently accepting new patients.

Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Referral may be required

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (0.4 miles away)
888-369-2427
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Hossein Borghaei is an Oncologist and a Radiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.

Expertise in
4
conditions
Dr. Rino S. Seedor
Hematology Oncology | Oncology
Expertise in
4
conditions
Dr. Rino S. Seedor
Hematology Oncology | Oncology
Referral may be required
Before you request

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (8.7 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rino Seedor is a Hematologist Oncology specialist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Seedor is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Metastatic Uveal Melanoma, Melanoma, Uveal Melanoma, and Melanoma of the Eye. Dr. Seedor is board certified in Medical Oncology. Dr. Seedor is currently accepting new patients.

Frequently Asked Questions about Dr. John C. Ruckdeschel

How do I make an appointment with Dr. John C. Ruckdeschel?

You can book an appointment with Dr. John C. Ruckdeschel by calling their office at 888-369-2427. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John C. Ruckdeschel a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John C. Ruckdeschel is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John C. Ruckdeschel specialize in?

While Dr. John C. Ruckdeschel is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John C. Ruckdeschel participate in research or clinical trials?

Yes. Dr. John C. Ruckdeschel has published 9 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. John C. Ruckdeschel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John C. Ruckdeschel accept my insurance?

Dr. John C. Ruckdeschel accepts most major insurance plans, including UnitedHealthcare. We recommend calling the office directly at 888-369-2427 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ruckdeschel's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile